Serum anti-GluA3 peptide A antibody dosage was significantly higher in FTD patients (0.41 ± 0.03 OD 450 nm) as compared to healthy controls (0.22 ± 0.14 OD 450 nm) (P < 0.001). This evidence concerns the gene GRIA3 and frontotemporal dementia.